DHCR Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of DHCR Antibodies for research in cholesterol biosynthesis and related pathways. DHCR Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DHCR, or 24-dehydrocholesterol reductase, catalyzes the final step of cholesterol synthesis by converting 24-dehydrocholesterol to cholesterol. DHCR maintains cellular membrane integrity and fluidity, while its dysregulation contributes to several diseases, including Smith-Lemli-Opitz syndrome and neurodegenerative disorders. Understanding DHCR function and regulation provides insights into cholesterol-related pathologies. Researchers worldwide rely on DHCR monoclonal antibodies to advance their studies in membrane biology and disease mechanisms. DHCR research continues to reveal new aspects of cholesterol metabolism and its impact on human health. Santa Cruz Biotechnology monoclonal antibodies enable researchers to make meaningful contributions to understanding cholesterol-related diseases.